Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04786262 | A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes | PHASE3 | RECRUITING | 52 | — | — | Mar 29, 2021 | Jun 30, 2030 | Mar 17, 2026 | 29 | United States, Canada +8 |
| Arm | Type | Description |
|---|---|---|
| VX-880 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| VX-880 | BIOLOGICAL | Infused into the hepatic portal vein. |
Key Inclusion Criteria: * Clinical history of T1D with \> 5 years of duration of insulin dependence * At least two episodes of documented severe hypoglycemia in the 12 months prior to enrollment * Stable diabetic treatment * Consistent use of continuous glucose monitor (CGM) for at least 3 months b...